« Return to News | Awards & Advancement

Covance Names New Periapproval Services Executives

Monday, December 29, 2008 11:15 AM

Global contract research organization (CRO) Covance has added three new senior executive positions to its periapproval services team. The Princeton, N.J.-based company appointed Glynis Neagle, M.D., vice president for medical affairs; Robert Bader, director for product safety services; and Thomas Noto, vice president for regulatory affairs.

Neagle, who previously served as Covance’s senior director for clinical development, will oversee medical affairs, epidemiology and product safety.

Bader, formerly senior director for global pharmacovigilance and epidemiology at Cephalon, will lead phase IIIb and IV pharmacovigilance programs.

Noto, who has held various senior positions at other CROs, will oversee regulatory affairs.

Other personnel news from the clinical trial industry:

Cincinnati-based CRO Medpace named Bernard Ilson, M.D., medical director. An expert in nephrology with over 21 years experience in clinical drug development, Ilson served as chief medical officer of Cardiokine before joining Medpace.

Praxis, a Nashville, Tenn.-based patient recruitment company, appointed Megan Sturm business development manager, overseeing Praxis’ northeast U.S. and southern California territories. Sturm spent 14 years at Pfizer before joining Praxis in 2006.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.